Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion
A placebo-controlled, double-blind, phase II clinical trial (the ELAD trial) testing liraglutide in over 200 patients with mild cognitive impairments/AD for 1 year showed that neuronal loss was reduced by the drug (Colin et al
Two groups of children were assigned: one group received conventional therapy plus 300,000 IU of vitamin D, while the other group received the standard therapy alone
Backed by 100+ peer-reviewed studies Pure & patented C15:0 ingredient Highest-standard manufacturing Every batch independently tested Generally Recognized as Safe (GRAS) Claims backed by Competent & Reliable Scientific Evidence (CARSE) 100,000+ active fatty15 subscribers 6,000+ 5 star reviews 70% of fatty15 customers report seeing or feeling benefits within 16 weeks, including:* Better sleep Improved energy Healthier mood Overall improved health Based on a survey with 6,243 fatty customers
Both are within safe parameters